Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors

Leukemia

Volumn 17, Issue 8, 2003, Pages 1508-1520

  Morgan, M A ^a   Wegner, J ^a   Aydilek, E ^a   Ganser, A ^a   Reuter, C W M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Farnesyltransferase inhibitors; Geranylgeranyl transferase I inhibitors; Myeloid leukemia; RAS signaling; Synergism

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; FARNESYL TRANS TRANSFERASE; GERANYLGERANYL TRANSFERASE 1 INHIBITOR; GGTI 2147; GGTI 286; GGTI 298; L 778123; LONAFARNIB; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; APOPTOSIS; ARTICLE; BONE MARROW CULTURE; BONE MARROW TOXICITY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA CELL; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN PROCESSING;

EID: 0043029517     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403022     Document Type: Article

References (75)

1. Bos JL. RAS oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
2. Clark GJ, Der CJ. Ras proto-oncogene activation in human malignancy. In: Garrett CT, Sell S (eds). Cellular Cancer Markers. Totowa, NJ: Humana Press, 1995, pp. 17-52.
3. Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 2000; 12: 157-165.
4. Rebollo A, Martinez CA. Ras proteins: recent advances and new functions. Blood 1999; 94: 2971-2980.
5. Reuter CWM, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematological malignancies? Blood 2000; 96: 1655-1669.
6. Mumby SM. Reversible palmitoylation of signaling proteins. Curr Opin Cell Biol 1997; 9: 148-154.
7. Wittinghofer A. Signal transduction via Ras. Biol Chem 1998; 379: 933-937.
8. Marshall CJ. Ras effectors. Curr Opin Cell Biol 1996; 8: 197-204.
9. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 1997; 7: 75-79.
10. Feig LA, Urano T, Cantor S. Evidence for a Ras/Ral signaling cascade. Trends Biochem Sci 1996; 21: 438-441.
11. Carpenter CL, Cantley LC. Phosphoinositide kinases. Curr Opin Cell Biol 1996; 8: 153-158.
12. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp U. The ins and outs of Raf kinases. Trends Biol Sci 1994; 19: 474-480.
13. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241-269.
14. Sinensky M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000; 1484: 93-106.
15. Omer CA, Kohl NE. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. Trends Pharmacol Sci 1997; 18: 437-444.
16. Gibbs JB, Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 1997; 37: 143-166.
17. Heimbrook DC, Oliff A. Therapeutic intervention and signaling. Curr Opin Cell Biol 1998; 10: 284-288.
18. Crul M, de Klerk GJ, Beijnen JH, Schellens JH. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs 2001; 12:163-184.
19. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18: 927-941.
20. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000; 60: 1871-1877.
21. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361-3369.
22. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol 2001; 38: 16-23.
23. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 1995; 55: 5310-5314.
24. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase 1 inhibitor in human tumor cell lines. Oncogene 1997; 15: 1283-1288.
25. James G, Goldstein JL, Brown MS. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci USA 1996;93: 4454-4458.
26. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995; 1: 792-797.
27. Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 1998; 58: 1253-1259.
28. Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME et al. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res 2000; 60: 2680-2688.
29. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997; 272: 14093-14097.
30. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459-14464.
31. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992; 89: 6403-6407.
32. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L et al. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 1997; 272: 10232-10239.
33. Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T et al. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood 1999; 94: 2469-2476.
34. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998; 16: 1467-1473.
35. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 1999; 59: 4919-4926.
36. Drexler HG, Matsuo AY, MacLeod AF. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res 2000; 24: 881-911.
37. Reuter C, Auf der Landwehr U, Schleyer E, Zuhlsdorf M, Ameling C, Rolf C et al. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony stimulating factor. Leukemia 1994; 8: 217-225.
38. Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 2001; 97: 1823-1834.
39. Reuter CWM, Catling AD, Weber MJ. Immune complex kinase assays for mitogen-activated protein kinase and MEK. Methods Enzymol 1995; 205: 245-256.
40. Reuter CWM, Catling AD, Jelinek T, Weber MJ. Biochemical analysis of MEK activation in NIH3T3 fibroblasts. J Biol Chem 1995; 270: 7644-7655.
41. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
42. Taylor JT, Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol 1996; 6: 1621-1627.
43. De Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997; 14: 623-625.
44. Taylor SJ, Resnick RJ, Shalloway D. Nonradioactive determination of Ras-GTP levels using activated ras interaction assay. Methods Enzymol 2001; 333: 333-342.
45. Krauter J, Hoellge W, Wattjes MP, Nagel S, Heidenreich O, Bunjes D et al. Detection and quantification of CBFB/MYHII fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. Genes, Chromosomes & Cancer 2001; 30: 342-348.
46. Johnson MR, Kangsheng W, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278: 175-184.
47. Chang JT, Chen IH, Liao CT, Wang HM, Hsu YM, Hung KF et al. A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 2002; 35: 591-596.
48. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
49. Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorg Med Chem 1998; 6: 293-299.
50. Tamanoi F, Gau C-L, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci 2001; 58: 1636-1649.
51. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000; 6: 2318-2325.
52. Sinensky M, Fantle K, Dalton M. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing. Cancer Res 1994; 54: 3229-3232.
53. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-1 inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 1997; 272: 27224-27229.
54. Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM et al. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 1997; 57: 1846-1850.
55. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000; 275: 30451-30457.
56. Ashar HR, James L, Gray K, Carr D, McGuirk M, Maxwell E et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) - > M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res 2001; 262: 17-27.
57. Sun J, Qian Y, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 1995; 55: 4243-4247.
58. Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 2000; 21: 113-116.
59. Prendergast GC. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 2000; 12: 166-173.
60. Lerner EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995; 270: 26770-26773.
61. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993; 260: 1658-1661.
62. Jelinek T, Catling AD, Reuter CW, Moodie SA, Wolfman A, Weber MJ. RAS and RAF-1 form a signalling complex with MEK-1 but not MEK-2. Mol Cell Biol 1994;14: 8212-8218.
63. Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995; 270: 26802-26806.
64. Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N et al. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. FEBS Lett 1999; 460: 235-240.
65. Di Paolo A, Danesi R, Caputo S, Macchia M, Lastella M, Boggi U et al. Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. Br J Cancer 2001; 84: 1535-1543.
66. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001; 61: 8758-8768.
67. Yang W, Tabancay AP, Urano J, Tamanoi F. Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol Microbiol 2001; 41: 1339-1347.
68. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989; 264: 20422-20429.
69. Beck LA, Hosick TJ, Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 1990; 110: 1489-1499.
70. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302-5309.
71. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001; 7: 3544-3550.
72. Liu AX, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 2000; 20: 6105-6113.
73. Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 1999; 59: 5492-5496.
74. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999; 19: 1831-1840.
75. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 2000; 275: 17974-17978.